Handbook_Volume III

195 3. Terapie di supporto cal bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50 [21] Brissot E , Labopin M, Moiseev I et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. Journal of Hematology & Oncology (2020) 13:87 [22] Nagler A, Labopin, Dholaria B et al. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplantation and Cellular Therapy 28 (2022) 86.e186.e8 [23] A E C Broers, de Jong C N, Bakunina K et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022 Jun 14; 6(11): 3378–3385 [24] Locatelli F, Merli P, Pagliara D et al. Outcome of children with acute leukemia given HLA haploidentical HSCT after αß T-cell and B-cell depletion. Blood 2017;130(5):677–85 [25] Koreth J, Kim HT, Lange PB et al. Bortezomibbased immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica 2018;103 (3):522–30 [26] ] Armand P, Kim H, Sainvil M et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Hematol 2016;173(1):96–104 [27] Sandmaier B, Kornblit B, Storer B et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graftversus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol 2019;6(8):e409–18 [28] Cutler C, Logan B, Nakamura R et al. Tacrolimus/ sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014;124(8):1372–7 [29] Pidala J, Kim J, Jim H et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012;97(12):1882–9 [30] ] Pulsipher MA, Langholz B, Wall DA et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children N. Martinez-Cibrian et al. Blood Reviews 48 (2021) 100792 12 with ALL: a phase 3 children’s oncology group/pediatric blood and marrow transplant consortium trial. Blood 2014;123(13):2017–25 [31] Watkins B, Qayed M, McCracken C et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol 2021 Jun 10;39(17):1865-1877 [32] Chen Y-B, Shah NN, Renteria AS et al. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv 2019;3(23):4136–46 [33] Reshef R, Ganetsky A, Acosta EP et al. Extended CCR5 blockade for graft-versus-host disease prophylaxis improves outcomes of reduced-intensity unrelated donor hematopoietic cell transplantation: a phase II clinical trial. Biol Blood Marrow Transplant 2019;25(3):515–21 [34] Kennedy GA, Tey S-K, Curley C, Butler JP et al. Results of a phase III double-blind study of the addition of tocilizumab vs placebo to cyclosporine/methotrexate GVHD prophylaxis after HLA-matched allogeneic stem cell transplantation. Blood 2019;134(Suppl. 1):368 [35] Antin JH, Weisdorf D, Neuberg D et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002;100(10): 3479–83 [36] Hamadami M, Hofmeister CC, Jansak B et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant 2008;14(7):783–9. [37] Choi SW, Stiff P, Cooke K et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFRI levels correlate with better outcomes. Biol Blood Marrow Transplant 2012; 18(10):1525–32 [38] Choi SW, Braun T, Chang L et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014;15 (1):87–95 [39] Choi S, Braun T, Henig I et al. Vorinostat plus tacrolimus/ methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood 2017;130(15):1760–7.